Search Within

Howard Scher

Formats
  1. Journal Article (624)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (6)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1130)
  2. Genitourinary Oncology Service (1130)
  3. Solid Tumor Oncology Division (1130)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Molecular Pharmacology and Chemistry Program Faculty (229)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (111)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (8)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1130)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD
    Meeting Abstract

    Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P.; Yu, E. Y.; George, D. J.; Chi, K. N.; Summa, J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Hullings, M.; Carbone, E.; Barnett, E.; Sutton, R.; Jendrisak, A.; Landers, M. A.; Wang, Y.; Dittamore, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations
    Meeting Abstract

    Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Armstrong, A. J.; Al-Adhami, M.; Lin, P.; Parli, T.; Sugg, J.; Steinberg, J. L.; Tombal, B. F.; Sternberg, C. N.; De Bono, J. S.; Scher, H. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The Polycomb repressor complex 1 promotes recruitment of myeloid-derived suppressor cells and immune evasion during bone colonization in castration-resistant prostate cancer
    Meeting Abstract

    Su, W.; Zhang, B.; Han, H.; Chakraborty, G.; Zhou, B.; Su, J.; Yang, G.; Ouerfelli, O.; Rosen, N.; Scher, H. I.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells to direct management metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Dittamore, R.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • BRCA-mediated tumorigenesis is origin and cell-type dependent
    Meeting Abstract

    Jonsson, P.; Cheng, M. L.; Bandlamudi, C.; Srinivasan, P.; Chavan, S. S.; Friedman, N. D.; Rosen, E. Y.; Richards, A. L.; Bouvier, N.; Selcuklu, S. D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration resistant prostate cancer (mCRPC) prior to platinum based chemotherapy
    Meeting Abstract

    Fernandez, L.; Poirier, J.; Rodriguez, A.; Hulling, M.; Richardson, R.; Sutton, R.; Jiles, R.; Schonhoft, J.; Lee, J.; Ebrahim, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save